Erosive Esophagitis Market Size, Share, Industry Report 2031
Erosive Esophagitis Market Size, Share, Industry Report 2031
Segments - Erosive Esophagitis Market by Drug Class (Proton Pump Inhibitors, Potassium-Competitive Acid Blockers, Histamine-2 Receptor Antagonists and Others), by Age Group (Children and Adults), by End Use (Hospitals, Clinics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends and, Forecast 2023 – 2031
Upcoming
| Report ID :HC-6219
| 4.8 Rating
| 68 Reviews
| 250 Pages
| Format :
Report Description
Market Outlook:
The global erosive esophagitis market was USD 4,767.66 Million in 2022 and is anticipated to reach USD 21,157.27 Million by 2031, expanding at a CAGR of 18.4% during the forecast period.
Erosive esophagitis is a type of esophagitis caused by inflammation and damage to the lining of the esophagus. It is caused by the backflow of stomach acid into the esophagus, a condition known as gastroesophageal reflux disease (GERD). Symptoms of erosive esophagitis include chest pain, difficulty in swallowing, and odynophagia. The treatment for esophagitis depends on the underlying cause and how badly the tissue lining the esophagus is damaged.
For instance, according to report published in National Library of Medicine, in western countries, the prevalence of erosive esophagitis is approximately 10% to 20%, while in that in Asian countries is approximately 5%.
COVID-19 Impact on Global Erosive Esophagitis Market
The research report finds that the COVID-19 pandemic has had significant impact on the global erosive esophagitis market. With many companies suspending their manufacturing and transportation operations in different locations due to lockdowns and post-pandemic restrictions, the global erosive esophagitis market had significantly affected. However, the exclusion of healthcare related services from stringent pandemic regulations in many parts of the world helped several companies to survive during the COVID-19 pandemic period.
Artificial Intelligence (AI) Impact on the Global Erosive Esophagitis Market
Artificial intelligence has a significant impact on global erosive esophagitis market. AI is use in the field of esophageal diseases in the development of an AI-assisted diagnosis for cytological detection of esophageal squamous lesions. This technology is able to help in the early detection and diagnosis of esophageal diseases, including erosive esophagitis.
AI is able to analyze large amounts of data and identify patterns that may not be apparent to human analysts. This is expected to lead to the discovery of new treatments or therapies for erosive esophagitis, and the development of effective or curative therapies.
Macro-economic Factors
Healthcare Industry Growth
The healthcare industry is expected to grow at a rapid pace in the coming years due to growing population and addition of new hospitals, clinics, and health centers. The demand for healthcare services globally has increased rapidly in the recent years, due to the increasing prevalence of chronic diseases and non-communicable diseases. The expansion of the healthcare industry plays a substantial role in shaping the landscape of erosive esophagitis, impacting its epidemiology, management, and market dynamics.
Market Dynamics
Major Driver: Rising Prevalence of Gastroesophageal Reflux Disease
The rising prevalence of GERD is affecting the growth of erosive esophagitis in several ways. It is the part of GERD spectrum that leads to esophageal adenocarcinoma if not treated in the early stages. Conditions that increase the risk of GERD include obesity, smoking, pregnancy, hiatal hernia, delayed stomach emptying, eating certain trigger foods, and eating large meals or eating late at night. Approximately 30% of GERD cases are able to further progress into erosive esophagitis. Apart from the compromise on quality of life, prolonged esophagitis further encourages esophageal epithelium metaplasia and progression of adenocarcinoma.
For instance, a report published in National Library of Medicine states that the prevalence of GERD is 18.1%–27.8% in North America, 8.8%–25.9% in Europe, and 2.5%–7.8% in East Asia. This prevalence of GERD cases is directly increasing the demand for erosive esophagitis medications in the market.
Existing Restraint: High Risk of Side Effects and Risks Associated with Medications
The treatment for erosive esophagitis includes the use of several medications including esomeprazole and omeprazole. The medications used in the treatment are tend to develop various unintended effects including serious skin reactions and hypomagnesemia. It can lead to allergic reactions, severe diarrhea, and unusual tiredness or weakness. In severe progression of side effects, it leads to complications such as severe ulceration, gastrointestinal bleeding, and esophageal strictures. Therefore, the high-risk involvement in the treatment acts as a restraint for global erosive esophagitis market.
Emerging Opportunity: New Drug Discoveries Through Extensive Research and Development Activities
Increasing innovations in drug delivery systems and the development of efficient and safe drugs are expected to creative many lucrative opportunities in the erosive esophagitis market during the forecast period. For instance,
-
Phathom Pharmaceuticals erosive esophagitis drug vonoprazan is a potassium-competitive acid blocker (P-CAB) under examination to relieve heartburn and heal all severities of erosive esophagitis. In a phase 3 PHALCON-EE trial, vonoprazan met the main goal of the trial in the healing phase, proving non-inferiority to Prevacid, a common over-the-counter medication for reducing acid and treating the symptoms of stomach and esophagus.
Scope of the Report
The report on the global erosive esophagitis market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Erosive Esophagitis Market– Global Industry Analysis, Size, Share, Growth, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Drug Class (Proton Pump Inhibitors, Potassium-Competitive Acid Blockers, Histamine-2 Receptor Antagonists and Others), Age Group (Children and Adults), End-use (Hospitals, Clinics, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered |
Camber Pharmaceuticals, Inc, DM Pharma, Haleon group of companies, HK inno.N Corporation, McNeil Consumer Pharmaceuticals Co, Pfizer Inc, Phathom Pharmaceuticals, Procter & Gamble, Soigner Pharma, Takeda Pharmaceuticals U.S.A., Inc, Teva Pharmaceuticals USA, Inc. |
Segmental Outlook
Based on drug class, the global erosive esophagitis market is segmented into proton pump inhibitors, potassium-competitive acid blockers, histamine-2 receptor antagonists, and others. The proton pump inhibitors segment is expected to hold a substantial share of the market during the forecast period, as it is an effective treatment for erosive esophagitis.
PPIs work by irreversibly blocking the H+/K+ ATPase enzyme or the gastric proton pump, which is found within the parietal cells of the stomach and is the final step of acid production. By undergoing acid-activation to sulfenamides, PPIs covalently bond to cysteine residues on the luminal surface of the proton pump, blocking ion transport and acid secretion. This effect enables healing of peptic ulcers, gastroesophageal reflux disease (GERD), Barrett’s esophagus, and Zollinger-Ellison syndrome.
Based on age group, the global erosive esophagitis market is classified as children and adults. The adult’s segment is projected to account for a significant share of the market during the forecast period, due to the rise in prevalence rate of the erosive esophagitis among adults. One of the primary causes of erosive esophagitis is chronic acid reflux or GERD, which is prevalent in adults, affecting at least 20% of the population.
On the basis of end-use, the global erosive esophagitis market is segmented into hospitals, clinics, and others. The hospital segment is projected to account for a significant share during the forecast period, as hospitals provide a wide range of medical services to patients, including treatment for erosive esophagitis. Hospitals have a wide range of specialized medical equipment, expertise, and resources as compared to other institutions making them equipped to handle the intensive care often required for erosive esophagitis.
In terms of distribution channel, the global erosive esophagitis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to expand at a significant CAGR during the forecast period. Hospital pharmacies are expected to register increased sales in the coming years, owing to its wide range of products, specialized expertise, integration with healthcare facilities, regulatory compliance, and comprehensive patient support and education.
Regional Outlook
On the basis of region, the global erosive esophagitis market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (MEA).
The erosive esophagitis market in North America accounted for a significant share of the market in 2022 owing to the rising number of patients with GERD. Over the last decade, there has been a significant increase in the proportion of young patients with GERD in North America, especially those within the age range of 30–39 years. For instance,
-
A report published in BioMed Central states that the prevalence of GERD in North America is estimated to be between 18.1% and 27.8%.
The erosive esophagitis market in Asia Pacific is projected to expand at a CAGR during the forecast period, owing to the growing awareness and diagnosis of GERD in developing nations. Moreover, the expansion of the healthcare sector in Asia Pacific and the growing research prospects are boosting the adoption of treatments for erosive esophagitis.
Key Benefits for Industry Participants & Stakeholders
-
In-depth Analysis of the Global Erosive Esophagitis Market
-
Historical, Current, and Projected Market Size in terms of Value
-
Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
-
Industry Drivers, Restraints, and Opportunities Covered in the Study
-
Recent Industry Trends and Developments
-
Competitive Landscape & Strategies of Key Players
-
Neutral Perspective on Global Erosive Esophagitis Market performance
Segments
Drug Class
- Proton Pump Inhibitors
- Potassium-Competitive Acid Blockers
- Histamine-2 Receptor Antagonists
- Others
Age Group
- Children
- Adults
End-use
- Hospitals
- Clinics
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players Profiled in the Report
- Camber Pharmaceuticals, Inc
- DM Pharma
- Haleon group of companies
- HK inno.N Corporation
- McNeil Consumer Pharmaceuticals Co
- Pfizer Inc
- Phathom Pharmaceuticals
- Procter & Gamble
- Soigner Pharma
- Takeda Pharmaceuticals U.S.A., Inc
- Teva Pharmaceuticals USA, Inc
Competitive Landscape
-
Manufacturers operating in the global erosive esophagitis market include Camber Pharmaceuticals, Inc, DM Pharma, Haleon group of companies, HK inno.N Corporation, McNeil Consumer Pharmaceuticals Co, Pfizer Inc, Phathom Pharmaceuticals, Procter & Gamble, Soigner Pharma, Takeda Pharmaceuticals U.S.A., Inc., and Teva Pharmaceuticals USA, Inc.
-
Market players are pursuing key strategies such as acquisitions, collaborations, and geographic expansion where a potential opportunity arises for the erosive esophagitis market.
-
In November 2023, Camber Pharmaceuticals, Inc. announced the addition of Famotidine Powder for oral suspension in its current portfolio. Famotidine is an antihistamine used to treat and prevent ulcers in the stomach and intestines and other conditions caused by excess stomach acid.
-
In June 2022, Glenmark Pharmaceuticals Ltd acquired the approved generic versions of several over-the-counter drugs from Wockhardt Ltd in the United States. The acquisition by the company's fully owned subsidiary Glenmark Pharmaceuticals Inc, USA includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets (10 mg and 20 mg) used to treat and prevent ulcers in the stomach and intestine, including heartburn, acid reflux, indigestion, and many other symptoms.
Frequently Asked Questions
Additional company profiles can be provided on request. For a discussion related to the above findings, click Speak to Analyst
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
Rising Prevalence of GERD, Growing Awareness Regarding Erosive Esophagitis Diagnosis and Treatment, and Increasing Funds Provided by Government for Medical Research on Drugs are the factors driving the growth of the Erosive Esophagitis Market.
According to this Growth Market Reports report, the Erosive Esophagitis Market is likely to register a CAGR of 18.4% during the forecast period 2022-2031, with an anticipated valuation of USD 21,157.27 Million by the end of 2031.
Adults and Children are the end-user of Erosive Esophagitis.
Growing Population, Government Healthcare Policies, and Healthcare Industry Growth are expected to act as macroeconomic factors for the market.
Major manufacturers include Camber Pharmaceuticals, Inc, DM Pharma, Haleon group of companies, HK inno.N Corporation, McNeil Consumer Pharmaceuticals Co, Pfizer Inc, Phathom Pharmaceuticals, Procter & Gamble, Soigner Pharma, Takeda Pharmaceuticals U.S.A., Inc, Teva Pharmaceuticals USA, Inc., and others.
The outbreak of coronavirus disease in 2019 (COVID-19) hampered global economy, created global interdependence, and challenged governments of many nations. The long-term effects of the pandemic are expected to hamper various industries during the forecast period, especially across Eastern Europe, the European Union, Eastern & Central Asia, and the US.
In addition to market size (in US$ Million) Company Market Share (in % for the base year 2022) is available in the report. Moreover, additional data analysis can be provided on request.
The base year considered for the Global Erosive Esophagitis Market report is 2022. The complete analysis period is 2021 to 2031, wherein, 2016, and 2021 are the historic years, and the forecast is provided from 2023 to 2031.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Erosive Esophagitis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Erosive Esophagitis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Erosive Esophagitis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Erosive Esophagitis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Erosive Esophagitis Market Size & Forecast, 2016-2031
4.5.1 Erosive Esophagitis Market Size and Y-o-Y Growth
4.5.2 Erosive Esophagitis Market Absolute $ Opportunity
4.6 Global Erosive Esophagitis Market: Impact Of Key Regulations
4.7 Current & Emerging Trends
Chapter 5 Global Erosive Esophagitis Market Analysis and Forecast By Drug Class
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Drug Class
5.1.2 Basis Point Share (BPS) Analysis By Drug Class
5.1.3 Absolute $ Opportunity Assessment By Drug Class
5.2 Erosive Esophagitis Market Size Forecast By Drug Class
5.2.1 Proton Pump Inhibitors
5.2.2 Potassium-Competitive Acid Blockers
5.2.3 Histamine-2 Receptor Antagonists
5.2.4 Others
5.3 Market Attractiveness Analysis By Drug Class
Chapter 6 Global Erosive Esophagitis Market Analysis and Forecast By Age Group
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Age Group
6.1.2 Basis Point Share (BPS) Analysis By Age Group
6.1.3 Absolute $ Opportunity Assessment By Age Group
6.2 Erosive Esophagitis Market Size Forecast By Age Group
6.2.1 Children
6.2.2 Adults
6.3 Market Attractiveness Analysis By Age Group
Chapter 7 Global Erosive Esophagitis Market Analysis and Forecast By End Use
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By End Use
7.1.2 Basis Point Share (BPS) Analysis By End Use
7.1.3 Absolute $ Opportunity Assessment By End Use
7.2 Erosive Esophagitis Market Size Forecast By End Use
7.2.1 Hospital
7.2.2 Clinics
7.2.3 Others
7.3 Market Attractiveness Analysis By End Use
Chapter 8 Global Erosive Esophagitis Market Analysis and Forecast By Distribution Channel
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By Distribution Channel
8.1.2 Basis Point Share (BPS) Analysis By Distribution Channel
8.1.3 Absolute $ Opportunity Assessment By Distribution Channel
8.2 Erosive Esophagitis Market Size Forecast By Distribution Channel
8.2.1 Hospital Pharmacies
8.2.2 Retail Pharmacies
8.2.3 Online Pharmacies
8.3 Market Attractiveness Analysis By Distribution Channel
Chapter 9 Global Erosive Esophagitis Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 Erosive Esophagitis Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Erosive Esophagitis Analysis and Forecast
11.1 Introduction
11.2 North America Erosive Esophagitis Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Erosive Esophagitis Market Size Forecast By Drug Class
11.6.1 Proton Pump Inhibitors
11.6.2 Potassium-Competitive Acid Blockers
11.6.3 Histamine-2 Receptor Antagonists
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis By Drug Class
11.8 Absolute $ Opportunity Assessment By Drug Class
11.9 Market Attractiveness Analysis By Drug Class
11.10 North America Erosive Esophagitis Market Size Forecast By Age Group
11.10.1 Children
11.10.2 Adults
11.11 Basis Point Share (BPS) Analysis By Age Group
11.12 Absolute $ Opportunity Assessment By Age Group
11.13 Market Attractiveness Analysis By Age Group
11.14 North America Erosive Esophagitis Market Size Forecast By End Use
11.14.1 Hospital
11.14.2 Clinics
11.14.3 Others
11.15 Basis Point Share (BPS) Analysis By End Use
11.16 Absolute $ Opportunity Assessment By End Use
11.17 Market Attractiveness Analysis By End Use
11.18 North America Erosive Esophagitis Market Size Forecast By Distribution Channel
11.18.1 Hospital Pharmacies
11.18.2 Retail Pharmacies
11.18.3 Online Pharmacies
11.19 Basis Point Share (BPS) Analysis By Distribution Channel
11.20 Absolute $ Opportunity Assessment By Distribution Channel
11.21 Market Attractiveness Analysis By Distribution Channel
Chapter 12 Europe Erosive Esophagitis Analysis and Forecast
12.1 Introduction
12.2 Europe Erosive Esophagitis Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Erosive Esophagitis Market Size Forecast By Drug Class
12.6.1 Proton Pump Inhibitors
12.6.2 Potassium-Competitive Acid Blockers
12.6.3 Histamine-2 Receptor Antagonists
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis By Drug Class
12.8 Absolute $ Opportunity Assessment By Drug Class
12.9 Market Attractiveness Analysis By Drug Class
12.10 Europe Erosive Esophagitis Market Size Forecast By Age Group
12.10.1 Children
12.10.2 Adults
12.11 Basis Point Share (BPS) Analysis By Age Group
12.12 Absolute $ Opportunity Assessment By Age Group
12.13 Market Attractiveness Analysis By Age Group
12.14 Europe Erosive Esophagitis Market Size Forecast By End Use
12.14.1 Hospital
12.14.2 Clinics
12.14.3 Others
12.15 Basis Point Share (BPS) Analysis By End Use
12.16 Absolute $ Opportunity Assessment By End Use
12.17 Market Attractiveness Analysis By End Use
12.18 Europe Erosive Esophagitis Market Size Forecast By Distribution Channel
12.18.1 Hospital Pharmacies
12.18.2 Retail Pharmacies
12.18.3 Online Pharmacies
12.19 Basis Point Share (BPS) Analysis By Distribution Channel
12.20 Absolute $ Opportunity Assessment By Distribution Channel
12.21 Market Attractiveness Analysis By Distribution Channel
Chapter 13 Asia Pacific Erosive Esophagitis Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Erosive Esophagitis Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Erosive Esophagitis Market Size Forecast By Drug Class
13.6.1 Proton Pump Inhibitors
13.6.2 Potassium-Competitive Acid Blockers
13.6.3 Histamine-2 Receptor Antagonists
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis By Drug Class
13.8 Absolute $ Opportunity Assessment By Drug Class
13.9 Market Attractiveness Analysis By Drug Class
13.10 Asia Pacific Erosive Esophagitis Market Size Forecast By Age Group
13.10.1 Children
13.10.2 Adults
13.11 Basis Point Share (BPS) Analysis By Age Group
13.12 Absolute $ Opportunity Assessment By Age Group
13.13 Market Attractiveness Analysis By Age Group
13.14 Asia Pacific Erosive Esophagitis Market Size Forecast By End Use
13.14.1 Hospital
13.14.2 Clinics
13.14.3 Others
13.15 Basis Point Share (BPS) Analysis By End Use
13.16 Absolute $ Opportunity Assessment By End Use
13.17 Market Attractiveness Analysis By End Use
13.18 Asia Pacific Erosive Esophagitis Market Size Forecast By Distribution Channel
13.18.1 Hospital Pharmacies
13.18.2 Retail Pharmacies
13.18.3 Online Pharmacies
13.19 Basis Point Share (BPS) Analysis By Distribution Channel
13.20 Absolute $ Opportunity Assessment By Distribution Channel
13.21 Market Attractiveness Analysis By Distribution Channel
Chapter 14 Latin America Erosive Esophagitis Analysis and Forecast
14.1 Introduction
14.2 Latin America Erosive Esophagitis Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Erosive Esophagitis Market Size Forecast By Drug Class
14.6.1 Proton Pump Inhibitors
14.6.2 Potassium-Competitive Acid Blockers
14.6.3 Histamine-2 Receptor Antagonists
14.6.4 Others
14.7 Basis Point Share (BPS) Analysis By Drug Class
14.8 Absolute $ Opportunity Assessment By Drug Class
14.9 Market Attractiveness Analysis By Drug Class
14.10 Latin America Erosive Esophagitis Market Size Forecast By Age Group
14.10.1 Children
14.10.2 Adults
14.11 Basis Point Share (BPS) Analysis By Age Group
14.12 Absolute $ Opportunity Assessment By Age Group
14.13 Market Attractiveness Analysis By Age Group
14.14 Latin America Erosive Esophagitis Market Size Forecast By End Use
14.14.1 Hospital
14.14.2 Clinics
14.14.3 Others
14.15 Basis Point Share (BPS) Analysis By End Use
14.16 Absolute $ Opportunity Assessment By End Use
14.17 Market Attractiveness Analysis By End Use
14.18 Latin America Erosive Esophagitis Market Size Forecast By Distribution Channel
14.18.1 Hospital Pharmacies
14.18.2 Retail Pharmacies
14.18.3 Online Pharmacies
14.19 Basis Point Share (BPS) Analysis By Distribution Channel
14.20 Absolute $ Opportunity Assessment By Distribution Channel
14.21 Market Attractiveness Analysis By Distribution Channel
Chapter 15 Middle East & Africa (MEA) Erosive Esophagitis Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Erosive Esophagitis Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Erosive Esophagitis Market Size Forecast By Drug Class
15.6.1 Proton Pump Inhibitors
15.6.2 Potassium-Competitive Acid Blockers
15.6.3 Histamine-2 Receptor Antagonists
15.6.4 Others
15.7 Basis Point Share (BPS) Analysis By Drug Class
15.8 Absolute $ Opportunity Assessment By Drug Class
15.9 Market Attractiveness Analysis By Drug Class
15.10 Middle East & Africa (MEA) Erosive Esophagitis Market Size Forecast By Age Group
15.10.1 Children
15.10.2 Adults
15.11 Basis Point Share (BPS) Analysis By Age Group
15.12 Absolute $ Opportunity Assessment By Age Group
15.13 Market Attractiveness Analysis By Age Group
15.14 Middle East & Africa (MEA) Erosive Esophagitis Market Size Forecast By End Use
15.14.1 Hospital
15.14.2 Clinics
15.14.3 Others
15.15 Basis Point Share (BPS) Analysis By End Use
15.16 Absolute $ Opportunity Assessment By End Use
15.17 Market Attractiveness Analysis By End Use
15.18 Middle East & Africa (MEA) Erosive Esophagitis Market Size Forecast By Distribution Channel
15.18.1 Hospital Pharmacies
15.18.2 Retail Pharmacies
15.18.3 Online Pharmacies
15.19 Basis Point Share (BPS) Analysis By Distribution Channel
15.20 Absolute $ Opportunity Assessment By Distribution Channel
15.21 Market Attractiveness Analysis By Distribution Channel
Chapter 16 Competition Landscape
16.1 Erosive Esophagitis Market: Competitive Dashboard
16.2 Global Erosive Esophagitis Market: Market Share Analysis, 2022
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 Camber Pharmaceuticals, Inc
16.3.2 DM Pharma
16.3.3 Haleon group of companies
16.3.4 McNeil Consumer Pharmaceuticals Co
16.3.5 Pfizer Inc
16.3.6 Phathom Pharmaceuticals
16.3.7 Procter & Gamble
16.3.8 Soigner Pharma
16.3.9 Takeda Pharmaceuticals U.S.A., Inc
16.3.10 Teva Pharmaceuticals USA, Inc
Methodology
Related Reports
Some other reports from this category!
Our Clients
